HAYA Therapeutics

🚀 We're Hiring! Are you looking for joining a forward-thinking organization where your expertise and skills can make a difference in fostering innovation and bring to life breakthrough disease-modifying therapeutics? 🧬 Check Our Open Position Scientist in Obesity - San Diego, CA 🇺🇲 ➡️ Apply TODAY: https://shorturl.at/Q9oLd Please, share this post with your network or tag anyone you think would be a great addition to our team! 🤝 #Hiring #JoinHAYATeam g#CareerOpportunities #NowHiring #BiotechJobs

Provocative data recently appeared in JACC Journals from Hammersley et al., which finds that myocardial fibrosis is a better predictor of outcomes in cardiomyopathy than stratification by LVEF. If we can reduce fibrosis in cardiomyopathy, will better outcomes follow? #HAYAtherapeutics is developing an Antisense Oligo (#ASO) to target activated cardiac myofibroblasts which cause myocardial fibrosis. Our goal is to change the cell state and modify the disease. https://lnkd.in/e7vwxb4X

Fibroblast phenotypic switching is increasingly recognized as a key process in cardiac fibrosis and heart failure. This article by Thomas Thum and colleagues underscores the potential of targeting the reversible transition between quiescent fibroblasts and activated myofibroblasts to mitigate fibrosis and enhance cardiac function. At HAYA Therapeutics, our lead program, HTX-001, targets WISPER, a cardiac-specific lncRNA, to reprogram activated myofibroblasts, reduce collagen deposition, and address fibrosis at its core. These insights further validate the therapeutic promise of this approach in tackling the fundamental drivers of heart failure. https://lnkd.in/eHQdkEBr

🚀 We're Hiring! Join our growing team and help us to bring to life breakthrough disease-modifying therapeutics targeting the regulatory genome with the potential for greater efficacy, safety, and accessibility than existing treatments. 🧬 New Open Position Scientist in RNA Biology, Obesity and Metabolic Diseases - San Diego, CA 🇺🇲 ➡️ Apply TODAY: https://lnkd.in/dRAHX28b Please, share this post with your network or tag anyone you think would be a great addition to our team. Discover all open positions at: https://lnkd.in/eF-T7B2c #Hiring #JoinHAYATeam #CareerOpportunities #NowHiring #BiotechJobs #HAYATherapeutics

 🎙️Another Podcast, Another Insight! 🎙️   Following the engaging conversation on The Bio Report, Samir Ounzain, HAYA's CEO & Co-founder,  shared more insights at Swisspreneur podcast in conversation with Silvan Krähenbühl. 🚀 In this latest episode Samir dives into: -       His scientific background, career path from academia to the entrepreneurial world and the foundation of HAYA Therapeutics; -       The importance of a strong team and company culture; -       The future ahead of HAYA;   👉 Whether you’re/ want to become a startup founder, a biotech or science enthusiast, this episode is a must-listen! Samir even replied to the rapid fire question — “build a pharma company yourself or getting acquired by a large pharma company one day?” Curious? 🎧 Listen to learn more: https://lnkd.in/eTZYA5Y4 A big thank you to the Swisspreneur team for this opportunity!   #Swisspreneur #Podcast #Innovation #StartupJourney #Entrepreneurship #CEOInsights #HAYA    

🚀 HAYA CEO & co-founder, Samir Ounzain had an insightful conversation with Daniel Levine for the Bio Report podcast about how the “dark matter” of the human genome can be key to developing novel therapies with the potential address the root causes of diseases! 🧬   🎧 Listen here to learn more: https://lnkd.in/ghg8Y3kq   A big thank you to Daniel Levine for the chance to share our story and what we do at HAYA!   Levine Media Group #RegulatoryGenome #DarkMatter #lncRNA #TheBioReport #Innovation #biotech #HAYA

We are one week away of the Dark Genome Symposium, and we are thrilled to be part of it! 🧬 Samir Ounzain, HAYA CEO & co-founder, and Diana Cruz, Computational Biologist, will be attending the meeting. Join us at the poster session to discover how we are leveraging the Dark Genome, beyond long non-coding RNAs, to develop medicines capable to promote partial cellullar reprogramming through antisense oligonucleotide targeting. ➡️ November 20th, 6-7:30pm EST HAYA mission - it’s not only to develop a new generation of medicine capable to solve the root causes of disease - it’s to promote a healthier aging and enable an extended health span for all. 🚀 Learn more: https://lnkd.in/ed5TrCgw #DarkGenomeSymposium #DGS2024 #HAYA

🚀 Targeting Regulatory Genome RNAs to Reprogram Disease Cell States - The HAYA Way to Fight Disease   The 2024 Nobel Prize in Physiology and Medicine recognizes the importance of RNA as more than just a messenger, highlights its critical role as an important regulator of cells and their function.   🧬 At HAYA, our mission is clear: bring to patients’ transformative medicines targeting Regulatory Genome RNAs, capable to reprogram disease cells into healthy ones and with the potential to stop and reverse disease-associated processes like fibrosis. 💡 We invite you to learn more about HAYA in our profile article at Biopharma Dealmakers, where you will find: - Insights into regulatory genome RNAs and their key role in driving disease - Details about HAYA's unique platform and approach - Upcoming milestones and our latest achievements - Collaboration opportunities - partnering with biopharma companies with a complementary disease or modality expertise. ➡ https://lnkd.in/efUGws24 #RegulatoryGenome #Biotech #HealthcareInnovation #HAYA #FutureofHealthcare #ReprogramCellStates

🚀 If you’d like a glimpse into the exciting work we’re doing at HAYA Therapeutics and learn about our latest updates, don’t miss this recent interview with our CEO and co-founder, Samir Ounzain, at the RNA Leaders USA Congress!   Stay tuned for more exciting news! #RegulatoryGenome #lncRNA #RNATherapeutics #HAYATherapeutics #RNALeaders

🚀 Last week, we welcomed Carsten Merkwirth, PhD as HAYA's Senior Director, Biomarkers. Carsten brings a wealth of experience from biomarker discovery to clinical biomarker development for late-stage assets across multiple modalities and therapeutic areas, including fibrotic-related diseases, oncology, immunology and neuroscience. His career includes roles at Takeda, Biosplice Therapeutics and Ferring Pharmaceuticals. We are thrilled to start working with him to help us develop and implement biomarker strategies across HAYA’s pipeline, focusing on RNA-targeted therapeutics for long non-coding RNAs and the regulatory genome. 🎉Welcome to the team Carsten! Learn more at: https://lnkd.in/eh3U5fjH #Biomarkers #Welcome #RegulatoryGenome #HAYAteam